Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ResolveD-CAP: Vitamin D3 for Inflammation in Pneumonia
NCT02802722Completed
- Sponsor
- Queen Mary University of London
- Start
- Feb 2017
- Primary completion
- Dec 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, double-blind trial of vitamin d in community acquired pneumonia (CAP) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: Plasma IL-6 concentrations at 6 weeks. Started Feb 2017; status: completed.
02
Drugs
vitamin d
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT02802722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02802722.